Photodynamic Therapy in the Treatment of Squamous Cell Carcinoma of the Head and Neck

Wenig, Barry L.; Kurtzman, Daniel M.; Grossweiner, Leonard I.; Mafee, Mahmood F.; Harris, David; Lobraico, Rocco V.; Prycz, Robert A.; Appelbaum, Edward L.

doi:10.1001/archotol.1990.01870110039003

Cited by 108 publications

(46 citation statements)

References 24 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…PDT has been used as an experimental clinical modality for some years and has recently been approved for clinical use in Japan, Canada, The Netherlands, United States and France in specific malignant and premalignant conditions. Most experience has been gained with the photosensitizing agent di-hematoporphyrin ether/ester (Photofrin, Quadralogic Technology, Vancouver, Canada), which has been shown to be of benefit in a range of clinical situations (Grant et al, 1993a and b;Wenig et al, 1990). This first generation photosensitizer has, however, a number of limitations.…”

mentioning

confidence: 99%

Photodynamic therapy using mTHPC for malignant disease in the oral cavity

et al. 1997

View full text Add to dashboard Cite

mentioning

confidence: 99%

Photodynamic therapy using mTHPC for malignant disease in the oral cavity

et al. 1997

View full text Add to dashboard Cite

“…A small number of clinical pilot studies have tentatively investigated the use of PDT in the treatment of oral cavity malignancy (Buchanan et al, 1989;Carruth & McKenzie, 1985;Feyh et al, 1990;Gluckman, 1986;Schuller et al, 1985;Wenig et al, 1990;Wile et al, 1984). All these studies used haematoporphyrin derivative (HPD) as the photosensitiser and included only a small number of patients with tumours of varying histological type, stage and site.…”

mentioning

confidence: 99%

A study of the effects of photodynamic therapy on the normal tissues of the rabbit jaw

Meyer

Speight²,

Bown³

1991

Br J Cancer

View full text Add to dashboard Cite

Summary Photodynamic therapy (PDT) is an anti-cancer treatment which involves the systemic administration of a photosensitising drug which is preferentially absorbed by tumour tissue. Relatively little drug should be absorbed by the surrounding normal tissues. Tumour destruction is achieved when the tumour is illuminated with light of a wavelength which activates the photosensitising drug thereby inducing a cytotoxic reaction. However studies in many tissues have shown that the hoped for tumour selectivity is rarely achieved. Using the rabbit mandible and gingiva as our models we have studied the effects of various doses of PDT on the tissues of the oral cavity, namely mucosa, bone, muscle and salivary gland. The photosensitiser used was di-sulphonated aluminium phthalocyanine. Results show that whereas bone is extremely resistant to PDT the other tissues are vulnerable to it. In the case of muscle and salivary gland this susceptibility is very much dose related. In salivary tissue necrotising sialometaplasia was observed in areas of the gland adjacent to those that had undergone necrosis. All tissues were noted to heal or regenerate well following PDT injury.

show abstract

“…Photofrin, HpD and topical ALA have been used in the clinic for the treatment of squamous cell carcinoma [60][61][62][63][64]. A dose of 2 mg/kg BW of Photofrin with a light fluence of 150-250 J/cm 2 or HpD at a dose of 5 mg/kg BW with a light fluence of 30 J/cm 2 had a good tumor response [63].…”

Section: Squamous Cell Carcinomamentioning

confidence: 99%

Perspectives of Photodynamic Therapy for Skin Diseases

Colussi¹,

Feyes²,

Mukhtar³

1998

Skin Pharmacol Physiol

View full text Add to dashboard Cite

Photodynamic therapy (PDT) is largely an experimental modality for the treatment of neoplastic and selected nonneoplastic diseases. This therapeutic procedure, through a cascade of events, leads to cell killing. In the past few years, dermatology has taken advantage of PDT for the treatment of skin cancer and other skin diseases. The skin has considerable attributes over many other organs for the application of PDT. These include the accessibility to all three PDT essential requirements; the drug (photosensitizing agent), visible light and oxygen. The major benefit of experimental PDT in dermatology is the ability to assess the clinical response visually and the relative ease in obtaining biopsies for precise biochemical and histological analysis. Currently, PDT has received approval worldwide for the ablation of various tumor types. In the United States, the Food and Drug Administration has approved PDT for the treatment of advanced esophageal cancer and selected patients with lung cancer. Clinical trials, employing several types of photosensitizers for PDT, are ongoing for a variety of dermatological lesions. This review summarizes current knowledge of PDT in dermatology and highlights future perspectives of this modality for effective management of skin diseases.

show abstract

Photodynamic Therapy in the Treatment of Squamous Cell Carcinoma of the Head and Neck

Cited by 108 publications

References 24 publications

Photodynamic therapy using mTHPC for malignant disease in the oral cavity

Photodynamic therapy using mTHPC for malignant disease in the oral cavity

A study of the effects of photodynamic therapy on the normal tissues of the rabbit jaw

Perspectives of Photodynamic Therapy for Skin Diseases

Contact Info

Product

Resources

About